Purple Biotech Ltd.

2.68
0.04 (1.52%)
At close: Apr 02, 2025, 3:44 PM
2.70
0.81%
After-hours: Apr 02, 2025, 06:26 PM EDT
1.52%
Bid 2.52
Market Cap 35.51K
Revenue (ttm) n/a
Net Income (ttm) n/a
EPS (ttm) -49.9
PE Ratio (ttm) -0.05
Forward PE -2.1
Analyst Buy
Ask 2.93
Volume 3,502
Avg. Volume (20D) 25,536
Open 2.64
Previous Close 2.64
Day's Range 2.64 - 2.78
52-Week Range 2.00 - 20.60
Beta 0.29

About PPBT

Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug for cancer patients in the United States. Its oncology pipeline includes CM24, a monoclonal antibody that blocks carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 1b/2 clinical trials for the treatment of non-small cell lung cancer and panc...

Industry Biotechnology
Sector Healthcare
IPO Date Nov 20, 2015
Employees 9
Stock Exchange NASDAQ
Ticker Symbol PPBT
Full Company Profile

Analyst Forecast

According to 1 analyst ratings, the average rating for PPBT stock is "Buy." The 12-month stock price forecast is $33, which is an increase of 1130.61% from the latest price.

Stock Forecasts
1 month ago
+3.87%
Purple Biotech shares are trading higher after the... Unlock content with Pro Subscription
1 month ago
+3.87%
Purple Biotech Advances NT219 Into a Phase 2 Study In Head And Neck Cancer